148 related articles for article (PubMed ID: 18838917)
1. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms.
Adams H; Liebisch P; Schmid P; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):96-101. PubMed ID: 18838917
[TBL] [Abstract][Full Text] [Related]
2. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker.
Torlakovic E; Torlakovic G; Nguyen PL; Brunning RD; Delabie J
Am J Surg Pathol; 2002 Oct; 26(10):1343-50. PubMed ID: 12360049
[TBL] [Abstract][Full Text] [Related]
3. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
Tiacci E; Pileri S; Orleth A; Pacini R; Tabarrini A; Frenguelli F; Liso A; Diverio D; Lo-Coco F; Falini B
Cancer Res; 2004 Oct; 64(20):7399-404. PubMed ID: 15492262
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
Nasr MR; Rosenthal N; Syrbu S
Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
[TBL] [Abstract][Full Text] [Related]
5. Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.
Chu PG; Loera S; Huang Q; Weiss LM
Am J Clin Pathol; 2006 Oct; 126(4):534-44. PubMed ID: 16938666
[TBL] [Abstract][Full Text] [Related]
6. B-cell transcription factor expression and immunoglobulin gene rearrangement frequency in acute myeloid leukemia with t(8;21)(q22;q22).
Johnson RC; Ma L; Cherry AM; Arber DA; George TI
Am J Clin Pathol; 2013 Sep; 140(3):355-62. PubMed ID: 23955454
[TBL] [Abstract][Full Text] [Related]
7. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.
Browne P; Petrosyan K; Hernandez A; Chan JA
Am J Clin Pathol; 2003 Nov; 120(5):767-77. PubMed ID: 14608905
[TBL] [Abstract][Full Text] [Related]
8. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias.
Zhang X; Lin Z; Kim I
J Korean Med Sci; 2003 Dec; 18(6):804-8. PubMed ID: 14676435
[TBL] [Abstract][Full Text] [Related]
9. PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage.
Cattoretti G; Angelin-Duclos C; Shaknovich R; Zhou H; Wang D; Alobeid B
J Pathol; 2005 May; 206(1):76-86. PubMed ID: 15772984
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas.
Blakolmer K; Vesely M; Kummer JA; Jurecka W; Mannhalter C; Chott A
Mod Pathol; 2000 Jul; 13(7):766-72. PubMed ID: 10912936
[TBL] [Abstract][Full Text] [Related]
11. Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases.
Tzankov A; Zimpfer A; Pehrs AC; Lugli A; Went P; Maurer R; Pileri S; Dirnhofer S
Mod Pathol; 2003 Nov; 16(11):1141-7. PubMed ID: 14614054
[TBL] [Abstract][Full Text] [Related]
12. The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms.
Jensen KC; Higgins JP; Montgomery K; Kaygusuz G; van de Rijn M; Natkunam Y
Mod Pathol; 2007 Aug; 20(8):871-7. PubMed ID: 17529924
[TBL] [Abstract][Full Text] [Related]
13. Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker.
Willmann M; Müllauer L; Guija de Arespacochaga A; Reifinger M; Mosberger I; Thalhammer JG
Vet Immunol Immunopathol; 2009 Apr; 128(4):359-65. PubMed ID: 19100628
[TBL] [Abstract][Full Text] [Related]
14. Comparison between CD19 and CD20 expression patterns on acute leukemic cells.
Ning BT; Tang YM; Chen YH; Shen HQ; Qian BQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):943-7. PubMed ID: 16403255
[TBL] [Abstract][Full Text] [Related]
15. CD3-and CD20-negative extramedullary non-Hodgkin leukemia/lymphoma: a histopathological study of 118 cases.
Maeshima AM; Taniguchi H; Hattori D; Sasaki H; Hori Y; Makita S; Iwaki N; Fukuhara S; Munakata W; Suzuki T; Izutsu K
Hum Pathol; 2022 Jun; 124():14-23. PubMed ID: 35307403
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic uses of Pax5 immunohistochemistry.
Feldman AL; Dogan A
Adv Anat Pathol; 2007 Sep; 14(5):323-34. PubMed ID: 17717432
[TBL] [Abstract][Full Text] [Related]
17. Oct2 and Bob1 are sensitive and specific markers in lineage determination of B cell lymphomas with no expression of conventional B cell markers.
Yin L; Xu J; Li M; Reddy V; Zhou Q; Liu H; Chu P; Zhang Q; Huang Q; Gao Z; Liang X; Wang HY; Pan Z
Histopathology; 2016 Nov; 69(5):775-783. PubMed ID: 27319306
[TBL] [Abstract][Full Text] [Related]
18. Level of PAX5 in differential diagnosis of non-Hodgkin's lymphoma.
Bharti B; Shukla S; Tripathi R; Mishra S; Kumar M; Pandey M; Mishra R
Indian J Med Res; 2016 May; 143(Supplement):S23-S31. PubMed ID: 27748274
[TBL] [Abstract][Full Text] [Related]
19. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.
Yu D; Allman D; Goldschmidt MH; Atchison ML; Monroe JG; Thomas-Tikhonenko A
Blood; 2003 Mar; 101(5):1950-5. PubMed ID: 12406913
[TBL] [Abstract][Full Text] [Related]
20. Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas.
Kanavaros P; Gaulard P; Charlotte F; Martin N; Ducos C; Lebezu M; Mason DY
Am J Pathol; 1995 Mar; 146(3):735-41. PubMed ID: 7887454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
